

# Blinatumomab with chemotherapy for consolidation treatment of Philadelphia- chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia

Information for the public

Published: 26 March 2025

[www.nice.org.uk](http://www.nice.org.uk)

Blinatumomab (Blinicyto) with chemotherapy is available on the NHS. It is a possible treatment for Philadelphia-chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in adults if:

- the leukaemia is minimal residual disease-negative
- it is used at the start of consolidation treatment.

Minimal residual disease refers to a small number of leukaemia cells that may remain in the body when the condition is in complete remission after treatment. Consolidation treatment is used after other stages of treatment and aims to prevent the cancer coming back.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on ALL](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Leukaemia Care](#), 08088 010 444
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6883-1